Equities

IDT Australia Ltd

IDT:ASX

IDT Australia Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.12
  • Today's Change0.00 / 0.00%
  • Shares traded37.34k
  • 1 Year change+101.99%
  • Beta1.2537
Data delayed at least 20 minutes, as of Sep 20 2024 06:44 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year IDT Australia Ltd grew revenues 100.81% from 7.03m to 14.12m while net income improved from a loss of 8.50m to a smaller loss of 5.41m.
Gross margin80.11%
Net profit margin-38.33%
Operating margin-42.18%
Return on assets-18.15%
Return on equity-22.75%
Return on investment-22.59%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at IDT Australia Ltd fell by 3.93m. Cash Flow from Financing totalled 6.77m or 47.92% of revenues. In addition the company used 9.60m for operations while cash used for investing totalled 1.09m.
Cash flow per share-0.0129
Price/Cash flow per share--
Book value per share0.0667
Tangible book value per share0.0667
More ▼

Balance sheet in AUDView more

IDT Australia Ltd has a Debt to Total Capital ratio of 16.01%.
Current ratio1.34
Quick ratio1.12
Total debt/total equity0.1906
Total debt/total capital0.1601
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.